Integra to develop modified artificial skin:
This article was originally published in Clinica
Executive Summary
Integra Life Sciences has received a $250,000 grant from the US National Institutes of Health to develop an RGD-peptide modified version of its INTEGRA artificial skin, a tissue-engineered product used to treat full-thickness burns and other skin injuries. Early pre-clinical trials indicated that the peptide-enhanced product could accelerate angiogenesis and lead to a faster rate of healing, said the Plainsboro, New Jersey-based company. Integra also received a recommendation for a Phase II grant worth $1.5 million, subject to satisfactory completion of the Phase I programme and certain other conditions.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.